DS-5565
Phase 3Small molecule
Daiichi SankyoDS-5565 is one of 166 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.
5
Indications
10
Total Trials
0
Active Trials
165
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1DS-5565
Daiichi SankyoPhase 3
Aranesp
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Flomax
SanofiPreclinical
Activase
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fibromyalgia4 trials
Peripheral Neuropathy2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DS-5565. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company